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Antonella Napolitano, I. Sadaf Farooqi, Edward T. Bullmore, and Paul C. FletcherBackground: Binge eating is associated with obesity and has been conceptualized as “food addiction.” However, this view has received
only inconsistent support in humans, and limited evidence relates key neurocircuitry to the disorder. Moreover, relatively few studies
have used pharmacologic functional magnetic resonance imaging to probe the underlying basis of altered eating behaviors.
Methods: In a double-blind, placebo-controlled, parallel group study, we explored the effects of a potent mu-opioid receptor
antagonist, GSK1521498, in obese individuals with moderate binge eating. Subjects were tested during a baseline placebo run-in period
and retested after 28-days of drug (n ¼ 21) or placebo (n ¼ 21) treatment. Using functional magnetic resonance imaging and behavioral
measures, we determined the drug’s effects on brain responses to food images and, separately, on motivation to expend energy to view
comparable images.
Results: Compared with placebo, GSK1521498 was associated with a significant reduction in pallidum/putamen responses to pictures
of high-calorie food and a reduction in motivation to view images of high-calorie food. Intriguingly, although motivational responding
was reduced, subjective liking for the same images actually increased following drug treatment.
Conclusions: Stimulus-specific putamen/pallidal responses in obese people with binge eating are sensitive to altered mu-opioid
function. This neuromodulation was accompanied by reductions in motivational responding, as measured by grip force, although
subjective liking responses to the same stimuli actually increased. As well as providing evidence for a link between the opioid system
and food-related behavior in binge-eating obese individuals, these results support a dissociation across measures of motivation and
liking associated with food-related stimuli in these individuals.Key Words: Binge eating, fMRI, hedonics, motivation, obesity,
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H
uman and animal studies of reward processing demon-
strate that motivation towards obtaining, and the hedonic
value of a reward, though highly related, are dissociable.
This has been framed as a dissociation between “wanting” and
“liking,” subserved by dopaminergic and opioidergic systems
respectively (1). Although this perspective has generated debate
and it has been pointed out that the dopamine-wanting per-
spective resonates strongly with a previously expressed view of
dopamine’s role in the “activation” of behaviors (2), there is a
broad consensus that behaviors may be highly motivated toward
the acquisition of outcomes even when those outcomes have
limited hedonic value, as in habitual responding (3). This
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http://dx.doi.org/10.1016/j.biopsych.2012.10.022(4,5), in which a critical element of the addictive process is the
transition to habitual behavior that is relatively insensitive to the
current hedonic value of the outcome.
A key mediator in the hedonic valuation process is the
mu-opioid receptor (MOR) system (6–12). In humans, mu-opioid
antagonists reduce the hedonic responses to, and consumption
of, palatable foods. The system also has a role in the motiva-
tional aspects of food-related behaviors (13), mediated by
interactions with dopaminergic systems (14). MORs localized on
inhibitory gamma-aminobutyric acid-ergic interneurons in the
ventral tegmental area (VTA) and hypothalamus can modulate
dopamine release in the nucleus accumbens and other dopami-
nergic target areas (15–17). Furthermore, MOR knockout mice
demonstrate decreased firing frequency (including reduced
bursting activity) of midbrain dopamine neurons (18) and
decreased dopamine reuptake in the nucleus accumbens (19).
The system has also been implicated in animal models of binge
eating, with MOR antagonism reducing such behaviour
(13,20,21). Although the effects are less clear in humans, there
is some genetic evidence that implicates the gain of function
118G polymorphism of OPRM1, the MOR gene, in binge eating
disorder (22).
It has been argued that a food addiction process is relevant to
the development of obesity, particularly in those who binge
(23,24). However the evidence supporting this in humans has
been questioned on clinical/behavioral (25) and neuroscientific
(26) grounds. A critical challenge in furthering the neuroscien-
tific exploration of this issue is establishing the functional
neuroanatomy and neurochemistry of the systems that sub-
serve motivation toward and enjoyment of foods and how
they may be perturbed in conditions such as binge eating.
Pharmacologic imaging studies offer a powerful way of
characterizing these systems and may offer insights thatBIOL PSYCHIATRY 2013;73:887–894
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Figure 1. Study design. Following screening and a 7-
day single-blind, placebo run-in, a baseline assessment
was performed during a 2-day stay on the clinical
research unit. This included the functional magnetic
resonance imaging (fMRI) and grip force tasks that are
the focus of this article. Thereafter, participants were
randomised to receive oral GSK1521498 (5 mg) or
placebo for 28 days. Further inpatient assessments were
performed on Day 14 and Day 28. fMRI and grip force
task were repeated on Day 28. Several other physical,
cognitive, and eating measures were performed over
the course of the visits (see Ziauddeen et al. [26] for
details).
888 BIOL PSYCHIATRY 2013;73:887–894 V.C. Cambridge et al.suggest ways of identifying, developing, and refining thera-
peutic strategies (13,27,28).
Previous pharmacologic imaging studies in obesity (29–35)
have focused largely on serotonergic and dopaminergic mechan-
isms; opioid mechanisms have received little investigation. Given
their critical role in food reward processing and potentially in
binge eating, as well as their implication in substance addictions
(36), further investigation of the MOR is warranted, both as
a potential pharmacologic target and as a neural system relevant
to the understanding of normal and aberrant eating behavior.
This study sought to examine this system using GSK1521498,
a potent antagonist with 14- to 20-fold selectivity for MORs, in
otherwise healthy, obese volunteers who were moderate binge
eaters. The aim was to determine, in the context of a clinical trial
of this drug’s effects on weight and eating behavior, the
concurrent changes in behavioral and neural responses to food
images in obese individuals with a target behavior potentially
sensitive to this receptor modulation.
In both preclinical models of obesity and binge eating (21,37)
and a Phase 1 study in healthy overweight humans (38), GSK1521498
has been shown to reduce food intake, particularly of high fat/
sugar foods. These findings were supported in this 28-day treat-
ment trial (39) in which treatment with GSK1521498 5 mg/day led
to a significant reduction in hedonic responses to high fat and
high sugar foods and a reduction in ad libitum consumption,
particularly of high fat foods. However, no overall weight loss was
found. Furthermore, in animal models, GSK1521498 has been
shown to reduce food seeking (21).
The tasks reported here were chosen to explore drug-related
changes in motivation and pleasure associated with food stimuli.
During functional magnetic resonance imaging (fMRI), subjects
viewed images of high and low calorie foods and high and low
reward nonfoods, making liking responses for each. In a novel,
complementary behavioral task outside the scanner, we mea-
sured the effort volunteers were willing to expend (on a grip
force transducer) to view images of different types and whether
drug treatment affected this effort measure and subjectively
rated “liking” responses.
Methods and Materials
Sixty-three volunteers (28 [44%] males) aged 18 to 60 years
(mean  SD, 41.5  10.0 years) endorsing moderate-severewww.sobp.org/journalbinge eating (Binge Eating Scale [BES] scores ‡19) (40,41)
(mean 26.4  6.7), and with body mass index ‡30 kg/m2
(mean 37.3  4.76 kg/m2), were enrolled in this study. The study
(identification number EudraCT 2009-016663-11, ClinicalTrials.gov
identifier NCT01195792) was approved by Berkshire Research
Ethics Committee (United Kingdom), and all participants provided
signed informed consent.
Study Design
In a double-blind, placebo-controlled, parallel-group design,
subjects received 1-week single-blind placebo run-in, followed by
4-week treatment with either placebo (n = 21), GSK1521498
2 mg/day (n = 21) or GSK1521498 5 mg/day (n = 21). Full details
of the study are reported elsewhere (39) and summarized in
Figure 1. On Day 1 (predrug), each participant underwent fMRI
scanning and the behavioral and eating measures described
subsequently. Following 28 days of treatment, subjects returned
for full evaluation and repeated all measures. Here we consider
only data from the placebo and GSK1521498 5 mg/day groups.
The 5-mg dose achieved 82% to 92% 24-hour MOR occupancy
compared with 64% to 80% with the 2-mg dose, which showed
no effect on eating behavior (39). Thus, data from the 2-mg
group were not analyzed here to minimize multiple comparisons
conducted in investigating drug effects at a dose unlikely to have
a pharmacodynamic effect.
fMRI Task. Participants fasted for 10 to 12 hours and
performed a simple task adapted from one reported previously
(34,42). The task entailed viewing and reporting subjective liking
for images from four categories: high-calorie foods (e.g., choco-
late), low-calorie foods (e.g., broccoli), rewarding nonfood items
(e.g., watches, jewelry) and less rewarding nonfood items (e.g.,
staplers). Images were matched across categories for color, size,
and background. Thirty images from each category were pre-
sented in blocks of 5, resulting in a total of 120 images over
24 blocks. Each image was presented for 4 sec with a 1-sec
intertrial interval (block length = 22 sec). Image blocks were
randomly interspersed with fixation periods. Participants were
instructed to press a button to indicate their liking for each
image with duration of button press indicating their rating. A
mixed-effects analysis of variance (ANOVA) model was used for
the behavioral analysis.
Image Acquisition and Analysis. Because of an initial
problem with task randomization, imaging data were unreliable
Table 1. Neural Responses at Day –1: High-Calorie Versus Low-Calorie
Food Images
V.C. Cambridge et al. BIOL PSYCHIATRY 2013;73:887–894 889for the first three participants. Eight participants could not
undergo both scanning sessions, and one could not fit into the
scanner. We therefore confine our analysis to the 30 reliable
datasets: 14 placebo (mean age 40.6  8.5 years, 6 men) and 16
drug (mean age 39.8  10.2 years, 8 men). Details on image
acquisition and preprocessing are in Supplement 1.
A two-stage masking procedure was used to maximize sen-
sitivity while minimizing the multiple comparisons problem. First,
an overall set of regions of interest (ROIs) was a priori defined
using the PickAtlas tool (43) implemented in SPM5 (Wellcome
Trust Centre for Neuroimaging, London, United Kingdom) and
consisted of the following bilaterally symmetric ROIs: nucleus
accumbens, caudate nucleus, putamen, globus pallidus, mid-
brain, prefrontal cortex, insula, hypothalamus, and amygdala. This
mask was further refined and constrained using data from all
participants combined at Day –1 (i.e., pretreatment) for the
analyses relating to the main effects of image type (all food vs.
nonfood and high-calorie vs. low-calorie images). This combined
anatomic/functional mask was used to test drug effects for
statistical significance while maintaining a family-wise error
(FWE) correction for multiple comparisons entailed by voxelwise
testing of the entire set of regions of interest.
Identifying Regional Responses and Drug Modulations of
Key Conditions. Initial analysis and defining the mask: the
purpose of the initial analysis was twofold: first to ensure that
across all individuals at baseline, the key task manipulation,
notably viewing high-compared with low-calorie food images,
produced activation in expected brain regions. This analysis
was restricted to the set of ROIs described earlier, and
FWE correction (p  .05) was used. Second, to identify brain
regions in which the response to high reward was specific toFigure 2. Functional magnetic resonance imaging task: liking ratings.
Subjective liking of food images was assessed (see Methods and
Materials) using duration of button press and is represented here in
milliseconds. Average values for each of the four image categories are
shown before (Day –1) and after (Day 28) drug and placebo treatment.
HC, high-calorie images; LC, low calorie images; NFR, nonfood rewarding
images; NFNR, nonfood, nonrewarding images.food images, another analysis was conducted assessing the
interaction of stimulus type (food and nonfood) with reward
value (high- vs. low-calorie food and high- versus low-reward
nonfood).
Analysis of drug effects: The mask defined earlier was used in
all the following analyses to characterize the effects of
GSK1521498 compared with placebo at Day 28. Three key
contrasts were tested:1.Reg
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were included in the analysis. This, of course, is not
independent of the foregoing analysis but was done for
completeness.3. Food type by drug by time (Day –1 and Day 28 data). Here we
examined the baseline and posttreatment scans for both
groups to assess the drug effects in terms of a change from
the baseline. Given that at this baseline, all subjects were at
the end of a 7-day placebo run-in, this analysis is presented for
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Regions demonstrating significant activation for high-calorie com-
ed with low-calorie images. All survive small volume family-wise error
rection for multiple comparisons.
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890 BIOL PSYCHIATRY 2013;73:887–894 V.C. Cambridge et al.other measures: for these secondary analyses, parameter esti-
mates were extracted from any region(s) showing a task-specificCorrelations of drug-related alteration in fMRI signal with
drug effect. We sought to determine whether variability in
weight change, ad libitum buffet meal intake (39) (Supplement 1),
BES scores, and effort expended on the grip force task were
related to neural changes in produced by GSK1521498 in the
drug group.
Grip Force Task. The purpose of this task was to examine the
physical effort participants were willing to expend to view
specific images and to relate this to their subsequent subjective
liking ratings of the images. Participants were seated approxi-
mately 60 cm from a computer screen and held a grip force
transducer (GFT) in one hand. The isometric GFT (TSD121C,
Biopac, Goleta, California) was connected to a Biopac MP150
unit through a Biopac DA100C module. This module was
interfaced with MATLAB (Mathworks, Natick, Massachusetts)
and Cogent (Laboratory of Neurobiology, University College of
London) on a standard laptop.
The task comprised 216 trials, each lasting 5 sec. On each trial,
two images appeared side by side onscreen: one large (300  300
pixels) and clearly visible (the default image), the other very small
(5  5 pixels) with the image content indeterminable (nondefault
image). Exerting force on the GFT would proportionately increase
the size of the nondefault image and shrink the default image. The
force required to maximally increase the size of the nondefault
image was set at 10% of each individual’s maximum grip force as
calibrated at the start of the task. Participants were instructed that
they could view images as they chose by squeezing more or less on
the grip force transducer, and were left alone for the duration of
the task.
Three categories of images were used: high-calorie food, low-
calorie food, and rewarding nonfood (e.g., jewelry, electronic
gadgets depending on gender). Each image pair comprised an
image from each of two categories. Every image was paired with
all images from the other two categories. The pairs were
counterbalanced with respect to the starting position on the
computer screen such that each image was presented on an
equal number of trials as the default and nondefault image.www.sobp.org/journalTherefore, for each image, there were an equal number of trials in
which expenditure of effort would enlarge it or reduce it. Finally
participants rated their liking for each image on a visual analogue
scale (0-100 mm).
Analysis. The force-time curves were transformed into a
summary measure for each image by averaging the area under
the curves across trials in which it was the nondefault image
(i.e., when effort would bring it to the foreground). Summary
force and liking measures were generated for each image
category for each subject. The change from baseline for both
force and liking measures were taken to a group-level ANOVA
with treatment group and category as factors. We also explored
correlations between grip force and liking scores and other
pharmacodynamic endpoints.
Results
fMRI Task
Behavioral Analysis. There was an overall effect of image
type, with higher liking ratings for food compared with nonfood
images [F(1,13) ¼ 10.1, p  .01; Figure 2]. There was also a main
effect of reward level with greater liking ratings for high-calorie
food and high-reward nonfood images [F(1,13) ¼ 34.7, p  .001].
In addition, there was a significant interaction between the
reward level and the image type with a greater difference in
liking ratings between high- and low-reward nonfood images
than between high- and low-calorie food images [F(1,13) ¼ 6.9,
p  .05]. No other main effects or interactions were significant,
and no significant drug effects were found.
Imaging Analysis. Initial analysis (Day –1; Figure 3 and
Table 1). A contrast across food images (high calorie  low
calorie) on baseline data (Day –1) using the mask of a priori
ROIs evoked significant activation within a large set of these
regions (Figure 3 and Table 1). As described, this analysis
constrained all subsequent analyses.
Effects of GSK1521498 on brain responses to food stimuli:1. Food type by drug interaction (Day 28 data). Right putamen/
pallidum (x, y, z ¼ 22, –17, 8; Z score ¼ 3.7; p  .05 FWEFigure 3. Functional magnetic resonance imaging
results at Day –1. The upper panel depicts the regions
of interest used on orthogonal maximum intensity
projections (“glass brains” viewed from the right (left
projection), from behind (middle) and from above
(right). The lower panels show the significant (p  .05,
uncorrected for display) areas of activation when con-
trasting viewing of high-calorie to low-calorie food
images at Day –1. This contrast used the placebo and
GSK1521498 treatment groups combined and shows
activity across key regions of reward circuitry. Full details
of the activation foci are presented in Table 1. Areas of
significant activation are rendered onto a standard
template image in Montreal Neurological Institute space
with sections chosen at the coordinates most appro-
priate to display the key activations. This activation map
was used as a mask to constrain subsequent analysis
exploring condition-specific effects of GSK1521498.
V.C. Cambridge et al. BIOL PSYCHIATRY 2013;73:887–894 891corrected for the ROI mask) was the only region showing a
significant attenuation of the neural response to high-calorie
food images (compared with low calorie) by GSK1521498.2. Stimulus type by reward by drug interaction (Day 28 data). A
significant effect was observed in the right putamen/pallidum
(x, y, z ¼ 22, –17, 8; Z score ¼ 3.7; p  .05 FWE), demonstrat-
ing that the drug effect on high calorie versus low calorie
images was greater than on high reward versus low reward
nonfood images (see Figure 4).3. Food type by drug by time. This analysis explored time-
dependent drug effects on high-calorie versus low-calorie
stimuli. Although there was a strong trend for a food type by
drug by time interaction in the same region of right putamen/
pallidum (x, y, z ¼ 22, –19, 8; Z score ¼ 2.7), this did not
survive correction for multiple comparisons within the
prespecified mask.Correlations between fMRI and behavioral measures: several
correlation analyses were carried out to explore the relationship
between drug effects on imaging, weight change, BES scores,
and eating behavior. Because these findings did not survive
multiple comparisons corrections, we treat these as preliminary
and speculative and do not discuss them further. In brief, there
was a correlation between drug-induced modulation of pallidal/
putamen activity and weight change (Spearman’s rho ¼ .46, one-
tailed p ¼ .038) and a trend toward correlation with reduction in
consumption of 60% fat dessert (Spearman’s rho ¼ .49, one-
tailed p ¼ .055)
Grip Force Task. Complete data were available for 40 parti-
cipants. One participant from each group was excluded from the
analysis because no baseline data were available. No significant
effect of drug group or visit was seen for the nonfood images
(Table S1 and Figure S1 in Supplement 1), so subsequent analyses
are presented only for food images. On Day –1, both groups wereon placebo and were pooled for the baseline analysis, there
being no significant group differences (force: F ¼ .1925, p ¼ .66,
liking: F ¼ .0159, p ¼ .9). Grip force for high-calorie images was
significantly greater than for low-calorie images (Figure 5, top
panel). Although this effect persisted after 28 days in the placebo
group, it was no longer significant following treatment with
GSK1521498. When the change from baseline (Figure 6) was
examined, a significant group-by-food-category interaction
(F ¼ 4.753, p ¼ .032) was observed. Thus, 5-mg GSK1521498
significantly attenuated the tendency to exert a greater grip to
view high-calorie compared with low-calorie images.
The liking ratings were not different for the high-fat images
compared with the low-fat at baseline; mean ratings for both
were moderately high, although this is at odds with the expended
effort. There was a significant effect of category in the ANOVA of
change from baseline scores (F ¼ 9.088, p ¼ .0035). This was
driven by the drug group, whose liking ratings increased for the
high-fat food images (p ¼ .0042), whereas their expended effort
decreased (Figure 5, top panel); the placebo group showed the
same pattern as at baseline.
Correlations were examined between grip force and subse-
quent liking rating. In brief, there was a significant positive
correlation between grip force and liking at baseline for the high-
calorie food images. This persisted in the placebo group on Day
28 but was no longer present following treatment with GSK1521498
(details in Figure 5, bottom panel).
Discussion
We examined the neural and behavioral responses to 28 days
of treatment with a potent MOR antagonist in obese people
with moderate binge eating. We demonstrate two key findings.
First, GSK1521498 produced a reduction in right pallidum/
putamen responses to high-calorie food images despite no effectFigure 4. Functional magnetic resonance imaging
(fMRI) results Day 28: drug-by-stimulus-by-reward inter-
action. fMRI results at Day 28 showing drug by stimulus
type (food vs. nonfood) by reward type (high calorie/
high reward vs. low calorie/low reward). The pallidum/
putamen region demonstrating this interaction (p  .05,
uncorrected for multiple comparisons for display) is
shown superimposed onto orthogonal sections of a
structural MRI in standard Montreal Neurological Insti-
tute space. In the lower right panel are plotted the
parameter estimates for each of the stimulus types after
placebo and GSK1521498 treatment. HC, high-calorie
images; LC, low calorie images; NFHR, nonfood high
reward images; NFNR, nonfood, nonrewarding images.
www.sobp.org/journal
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Figure 5. Grip force task: effort expended and liking ratings. The top panel shows the grip force exerted and the corresponding liking ratings at
baseline in both groups and separately for placebo and the GSK1521498 group at the end of treatment. It can be seen that the difference between force
exerted for high-fat (HF) versus low-fat (LF) food images is no longer significant after drug treatment, even though the subjective liking for these images is
higher. The bottom panel displays the correlations between the exerted force and liking ratings for the high-fat food images, again at baseline for both groups
and separately at Day 28. The correlation between these two measures is seen at baseline and in the placebo group at the end of treatment but is lost in the
drug group. *p  .05; **p  .01; ***p  .001.
892 BIOL PSYCHIATRY 2013;73:887–894 V.C. Cambridge et al.on subjective liking of the images. Second, although it reduced
effort expended to view high-calorie food images, there was,
unexpectedly, an increase in subjective liking ratings of those
same high-calorie foods. Moreover, although the motivational
measure correlated strongly with liking ratings before treatment,
this relationship was lost after drug administration. TheseFigure 6. Change from baseline in grip force and liking ratings. *p  .05;
**p  .01. HF, high fat; LF, low fat; PBO, placebo.
www.sobp.org/journalfindings complement a previous report (39) and suggest that,
in this group of obese people, the drug’s neural effects are
associated with a potentially therapeutic perturbation in the
relationship between motivation and subjectively experienced
pleasure for the high-calorie food images.
Before treatment, there was widespread activation in reward-
related regions to high-calorie food images, consistent with
previous studies (34,44,45). The drug’s impact was localized to
a brain region central to the motivational and hedonic compo-
nents of eating and has been postulated to be a final limbic
outflow pathway from the reward system (46). Although we
observed no impact of GSK1521498 on the liking ratings for
these images, it was associated with an increase in the liking
ratings for the images in the grip force task. This latter finding
is most intriguing, especially given that GSK1521498 has a nega-
tive impact on the pleasures associated with tasting highly
palatable foods (39,47). It appears that, following GSK1521498
treatment, although motivation (grip force) is reduced, the
verbal expression of liking distinguished high-calorie from low-
calorie food images, a pattern that was expected, but not
found, at baseline.
Clearly there is a disconnection between the imaging and
motivational measures and their respective liking measures.
An important consideration is that, in both these tasks, it is
not consummatory reward processing that is being examined.
It may be that the motor expression of motivation toward
food reflects a more implicit measure of participants’ attitudes
toward these high-calorie foods whereas the subjective liking
reflects a more explicit one influenced by other factors (e.g., the
reluctance that an obese person might have for publically
expressing strong liking for high-calorie foods or the contribution
V.C. Cambridge et al. BIOL PSYCHIATRY 2013;73:887–894 893of a healthiness attribute to low-calorie foods). In trying to
understand this, it is worth considering the precise locali-
zation of the drug’s effect (i.e., overlaying posterior globus
pallidus and putamen). It is tempting to speculate that this
drug modulation lies on the uppermost aspect of the globus
pallidus, but the spatial resolution does not allow definitive
localization. However given the clear evidence that the pallidum
is the site of a “hedonic hotspot” (6,46) rich in MORs and
is a key brain region subserving the hedonic-motivation interface,
the attenuating effects of an antagonist in precisely this region
strongly suggest that this may well be the pallidum. If so,
the localization of the effect in this region with an accom-
panying decrease in motivational responding indicates that
the effect of GSK1521498 is to disrupt motivational responding
to food or “food seeking” in the absence of actual reward
consumption. This is in keeping with the findings from
animal models wherein GSK1521498 reduces food seeking even
before the animal has first experienced the food after drug
administration (21). In the same animal model, the drug also
affected the amount of food consumed, a finding replicated in
humans (39).
This difference between anticipatory/motivational processes
and consummatory/hedonic processes may partly explain an
important limitation of these findings: why, aside from non-
significant correlations with weight change and high-fat
dessert consumption, the neural and motivational changes
associated with drug treatment did not predict behavioral
changes. Another limitation to be considered is the lack of
correlation between the neural and motivational measure,
which may relate to methodologic differences in the two
tasks, the imaging task featured single unique presentations of
multiple images and the GFT featuring multiple presentations
of a small set of images, each always in contrast with
another image.
How do these findings relate to food addiction? Clearly, the
exploration of opioid antagonist effects on motivational and
hedonic processes draws heavily on concepts emerging from, or
related to, the addiction literature. But do these findings support
or refute an addiction model of overeating? Two important
caveats must be stated. We did not have a non-binge-eating or
nonobese control group in this study. Second, all participants
were only moderate binge eaters. Bearing these in mind, our
findings show that the MOR system is clearly implicated in
motivational aspects of food reward, and these aspects can be
dissociated from the liking/expected reward of the food.
However the food addiction model, insofar as it has been
described in neural processing terms, predicts a dissociation in
the native state (i.e., the placebo condition) with enhanced
anticipatory reward and reduced consummatory reward, or
“wanting without liking” (48,49). Instead, we find that the
placebo group shows greater motivated responding to foods
they rate as highly liked, whereas treatment abolishes and
perhaps even reverses this effect. Although these ideas must
be treated as speculative, they do not support a food
addiction model of overeating. Nevertheless the findings are
important in two key regards. First, they add to the converging
lines of evidence that indicate a role for the opioid system in
binge eating. Second, they provide a critical element for
evaluating cognitive neuroscientific models of abnormal eat-
ing, including addiction models, by elucidating an integral part
of the functional neuroanatomical and neurochemical network
that subserves these behaviors.One additional, speculative point is that the neuromodulatory
effects of GSK1521498 appear to entail, in part, an enhanced
response to low calorie food images (see plot, Figure 4). Might
the impact of the drug reflect an additional, enhanced motivation
toward low-calorie foods? Although such an effect was not
elucidated by our behavioral measures, it is noteworthy that
dietary manipulations can lead to shifts in preference from high-
to low-fat foods in humans (50) and rats (51).
In summary, our findings suggest that a key mechanism of
action of GSK1521498 is a specific and significant reduction in
motivation toward high-calorie foods. This is in keeping with a
central role for the opioid system in food-related behavior in this
population and points to its importance in driving consumption
and overconsumption of high-calorie foods and the potential
therapeutic relevance of MOR antagonists, such as GSK1521498,
in mitigating such overconsumption.
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